BioRestorative Therapies Inc BRTX.OQ BRTX.O is expected to show a rise in quarterly revenue when it reports results on May 14 for the period ending March 31 2025
The Melville New York-based company is expected to report a 985.7% increase in revenue to $380 thousand from $35 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for BioRestorative Therapies Inc is for a loss of 32 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for BioRestorative Therapies Inc is $13.00, above its last closing price of $1.80.
This summary was machine generated May 10 at 00:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)